IGFBP2-L

Only IGFBP-2 was associated with increased tumor grade but not stage. Therefore, IGF-1, IGFBP-2, and IGFBP-3 may be useful as early detection and prognostic biomarkers in CRC.

IGFBP2 knockdown stopped mouse glioma and M2 macrophage polarization. CAF plays a pro-carcinogenic role in glioma, and the CAF-related gene IGFBP2 could promote glioma progression by inducing M2 macrophage polarization.

In summary, we present a novel nomogram based on the angiogenesis-related genes COL22A1, IGFBP2, and MPO that allows survival prediction in patients with grade 4 diffuse gliomas. Furthermore, our cellular assays support a pro-oncogenic role for COL22A1 in these tumors.

In this study, we found that MMP-2 plays a significant role in AML progression and may serve as a potential prognostic biomarker and therapeutic target for the effective management of AML.

The presented results indicate that CA 19-9 is a marker demonstrating high potential for PDAC and CP differentiation. The inclusion of additional variables into the model, such as the serum level of IGF-1 or IGFBP-2, slightly increased the sensitivity in differentiating CP from PDAC. The IGF-1/IGFBP-2 ratio turned out to be a good marker of pancreatic diseases, but insufficient for the purpose of CP and PDAC differentiation.

These findings provide frontier trend of IGFBPs related research and new clues for identifying novel therapeutic targets for various cancers.

Furthermore, expression of IGFBP2 mRNA was related to the occurrence of isocitrate dehydrogenase 1 (IDH1) mutation, high heat shock protein 27 (Hsp27) expression and telomerase reverse transcriptase  promoter mutation (TERTp) ( P = 0.013, 0.015 and 0.016, respectively), and patients with TERTp/IGFBP2 showed the shortest survival. In conclusion, IGFBP2 mRNA expression status is an independent prognostic biomarker in glioblastomas, and the combination of IGFBP2 mRNA and TERTp status might serve as a prognostic indicator in patients with glioblastoma.